FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion...
Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved...
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No...
CDI ‑ 988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections Company to present Phase 1 data and updates from ongoing Phase 1b study...
Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis...
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview...
Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $ 1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025...
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR)...
BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview...
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE)...